Enlivex Therapeutics Ltd (NASDAQ:ENLV) CEO Dr Oren Hershkovitz tells Proactive’s Stephen Gunnion that the Israeli Ministry of Health has approved a Phase I/II trial of the company’s proprietary immunotherapy drug candidate Allocetra.
Hershkovitz explains that the company is developing a pipeline for macrophage reprogramming in solid cancers and sepsis, the third-leading cause of mortality in the United States.
Enlivex has a cash runway extending into the third quarter of 2024 – and possibly beyond – and there are multiple clinical milestones investors should look out for, he adds.
#ProactiveInvestors #EnlivexTherapeutics #macrophages #Allocetra #Nasdaq
